CA Stock MarketDetailed Quotes
SZLS StageZero Life Sciences Ltd
- 0.040
- 0.0000.00%
15min DelayMarket Closed Apr 11 09:30 ET
4.94MMarket Cap-0.25P/E (TTM)
0.000High0.000Low0Volume0.000Open0.040Pre Close0.00Turnover0.05552wk High0.00%Turnover Ratio123.53MShares0.04052wk Low-0.163EPS TTM3.82MFloat Cap108.000Historical HighLossP/E (Static)95.50MShs Float0.035Historical Low-0.149EPS LYR0.00%Amplitude--Dividend TTM-0.36P/B1Lot Size--Div YieldTTM
StageZero Life Sciences Ltd Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -32.98%499.66K | -50.83%390.08K | -32.96%521.92K | -6.74%745.49K | -20.53%793.31K | -41.07%778.52K | -25.12%3.8M | -54.97%676.48K | 16.82%799.4K | 146.64%998.2K |
| Operating revenue | -32.98%499.66K | -50.83%390.08K | -32.96%521.92K | -6.74%745.49K | -20.53%793.31K | -41.07%778.52K | -25.12%3.8M | -54.97%676.48K | 16.82%799.4K | 146.64%998.2K |
| Cost of revenue | -1.35%569.26K | -43.09%382.27K | -48.40%221.38K | -12.71%577.08K | -38.05%671.75K | -68.48%429.07K | 7.92%4.2M | -29.09%1.09M | -18.12%661.08K | 77.77%1.08M |
| Gross profit | -141.33%-69.6K | -93.57%7.82K | -13.71%301.54K | 21.75%168.41K | 241.20%121.56K | 967.59%349.45K | -134.29%-403.75K | -992.64%-415.71K | 212.44%138.32K | 58.05%-86.09K |
| Operating expense | -69.59%282.52K | -25.39%703.1K | -62.32%616.73K | -39.21%929.15K | -50.92%942.31K | -36.92%1.64M | -20.17%7.43M | -56.74%1.31M | -35.76%1.53M | -10.04%1.92M |
| Selling and administrative expenses | -68.93%282.52K | -18.16%703.1K | -61.91%569.49K | -36.37%909.42K | -50.22%859.07K | -37.51%1.5M | -19.10%6.65M | -46.88%1.36M | -25.14%1.43M | -8.65%1.73M |
| -Selling and marketing expense | --0 | --0 | --0 | -124.77%-12.66K | -82.44%16.65K | -84.36%76.13K | -39.99%746.41K | -41.24%113.66K | -77.61%51.11K | -77.45%94.8K |
| -General and administrative expense | -69.36%282.52K | -16.54%703.1K | -59.87%569.49K | -33.09%922.08K | -48.35%842.43K | -25.54%1.42M | -15.37%5.91M | -47.34%1.25M | -18.02%1.38M | 11.04%1.63M |
| Research and development costs | --0 | --0 | --0 | -80.15%19.73K | -57.10%83.23K | -51.82%61.01K | -54.55%351.99K | -114.32%-68.08K | -56.35%99.4K | 171.44%194.03K |
| Depreciation amortization depletion | ---- | ---- | 111.91%18.28K | ---- | ---- | -6.43%8.63K | -6.71%35.81K | 1.38%-123.02K | ---- | ---- |
| -Depreciation and amortization | ---- | ---- | 111.91%18.28K | ---- | ---- | -6.43%8.63K | -6.71%35.81K | 1.38%-123.02K | ---- | ---- |
| Other operating expenses | ---- | ---- | -59.81%28.96K | ---- | ---- | 8.47%72.05K | 43.07%390.5K | 17.30%142.81K | ---- | ---- |
| Operating profit | 53.71%-352.12K | 15.29%-695.28K | 75.52%-315.19K | 45.28%-760.73K | 59.09%-820.75K | 51.15%-1.29M | 3.65%-7.83M | 43.75%-1.73M | 44.45%-1.39M | 14.25%-2.01M |
| Net non-operating interest income (expenses) | -75.60%-47.16K | 47.27%-52.67K | 70.86%-40.75K | 61.27%-26.85K | -108.13%-99.88K | -223.77%-139.84K | -41.82%-284.07K | -174.44%-123.63K | -4.16%-69.34K | 3.37%-47.99K |
| Non-operating interest expense | 75.60%47.16K | -47.27%52.67K | -70.86%40.75K | -61.27%26.85K | 108.13%99.88K | 223.77%139.84K | 9.44%219.21K | 30.46%58.77K | 4.16%69.34K | -3.37%47.99K |
| Total other finance cost | ---- | ---- | ---- | ---- | ---- | ---- | --64.86K | ---- | ---- | ---- |
| Other net income (expenses) | -81.03%98.49K | 92.35%-29.41K | -102.42%-34.29K | -32.78%519.09K | -118.42%-384.55K | -489.16%-3.3M | -1,029.24%-7.65M | 307.11%1.41M | -88.51%772.28K | |
| Gain on sale of security | ---- | -81.22%98.49K | 92.19%-29.41K | -103.05%-34.29K | --524.5K | -128.61%-376.37K | -17.39%2.27M | -144.58%-249.83K | 6.39%1.13M | ---- |
| Special income (charges) | ---- | ---- | ---- | ---- | ---- | ---- | -611.39%-5.53M | -2,906.74%-7.36M | 138.67%288.24K | 386.10%772.28K |
| -Less:Restructuring and mergern&acquisition | ---- | ---- | ---- | ---- | ---- | ---- | -335.73%-1.83M | --0 | -138.67%-288.24K | -386.10%-772.28K |
| -Less:Impairment of capital assets | ---- | ---- | ---- | ---- | ---- | ---- | --7.36M | ---- | ---- | ---- |
| Other non-operating income (expenses) | ---- | ---- | ---- | ---- | ---5.41K | ---8.18K | 97.14%-31.97K | ---31.96K | -100.04%-12 | ---- |
| Income before tax | 51.42%-399.28K | -61.74%-649.46K | 78.68%-386.35K | -1,722.52%-821.88K | 68.67%-401.54K | -206.84%-1.81M | -52.53%-11.42M | -313.78%-9.5M | 97.97%-45.1K | -129.60%-1.28M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Earnings from equity interest net of tax | ||||||||||
| Net income | 51.42%-399.28K | -61.74%-649.46K | 78.68%-386.35K | -1,722.52%-821.88K | 68.67%-401.54K | -206.84%-1.81M | -52.53%-11.42M | -313.78%-9.5M | 97.97%-45.1K | -129.60%-1.28M |
| Net income continuous operations | 51.42%-399.28K | -61.74%-649.46K | 78.68%-386.35K | -1,722.52%-821.88K | 68.67%-401.54K | -206.84%-1.81M | -52.53%-11.42M | -313.78%-9.5M | 97.97%-45.1K | -129.60%-1.28M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 51.42%-399.28K | -61.74%-649.46K | 78.68%-386.35K | -1,722.52%-821.88K | 68.67%-401.54K | -206.84%-1.81M | -52.53%-11.42M | -313.78%-9.5M | 97.97%-45.1K | -129.60%-1.28M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 51.42%-399.28K | -61.74%-649.46K | 78.68%-386.35K | -1,722.52%-821.88K | 68.67%-401.54K | -206.84%-1.81M | -52.53%-11.42M | -313.78%-9.5M | 97.97%-45.1K | -129.60%-1.28M |
| Diluted earnings per share | 67.68%-0.0032 | -60.67%-0.0053 | 84.37%-0.0031 | -2,152.25%-0.01 | 67.28%-0.0033 | -100.00%-0.02 | 0.00%-0.11 | -80.00%-0.09 | 97.78%-0.0004 | -120.00%-0.01 |
| Basic earnings per share | 67.68%-0.0032 | -60.67%-0.0053 | 84.37%-0.0031 | -2,152.25%-0.01 | 67.28%-0.0033 | -100.00%-0.02 | 0.00%-0.11 | -80.00%-0.09 | 97.78%-0.0004 | -120.00%-0.01 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CA
Overall
Symbol
Price
% Chg
No Data